mdma users, cognition, 5HT
Conditions
Interventions
Subjects will be treated with combinations of:
1. Ketanserin 50mg / MDMA 75mg (treatment 1)
2. Pindolol 20mg / MDMA 75mg (treatment 2)
3. Placebo / MDMA 75mg (treatment 3)
4. Pindolol 20 mg / placebo (treatment 4)
5. Ketaserin 50mg / placebo (treatment 5)
6. Placebo / placebo (treatment 6).
Drugs and placebo will be administered orally in identically appearing formulations. MDMA is administered as a 25 ml solution in bitter orange peel syrup, which is
Sponsors
NWO
Eligibility
Inclusion criteria
Inclusion criteria: 1. Between 18 and 40 years of age; 2. Experience with the use of MDMA (at least 5 times, of which no less than one in the past 12 months); 3. Free from psychotropic medication; 4. Good physical health as determined by examination and laboratory analysis; 5. Absence of any major medical, endocrine and neurological condition; 6. Normal weight, body mass index (weight/length2) between 18 and 28 kg/m2; 7. Health insurance; 8. Written informed consent.
Exclusion criteria
Exclusion criteria: 1. History of drug abuse (other than the use of MDMA) or addiction; 2. Pregnancy or lactation; 3. Cardiovascular abnormalities as assessed by standard 12-lead ECG; 4. Excessive drinking (> 20 standard alcoholic consumptions a week); 5. Smoking (>10 sigarettes a day); 6. Hypertension (diastolic> 100; systolic> 170); 7. Use of psychotropic medication; 8. History of psychiatric or neurological disorder.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Neurocognitive measures of memory and impulse control. | — |
Contacts
Public ContactJ.G. Ramaekers
Maastricht University Dept of Neuropsychology & Psychopharmacology, Faculty of Psychology and Neuroscience, P.O. Box 616
Outcome results
None listed